BFM
TXG icon

Boothbay Fund Management’s 10x Genomics TXG Stock Holding History

Boothbay Fund Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-82
Closed -$1.48M – 2126
2021
Q1 		$1.48M Buy
+82
New +$14.2K 0.06% 437

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

Boothbay Fund Management's TXG Position: Q2 2023 in Review

Boothbay Fund Management sold out of 10x Genomics (TXG) in Q2 2023, closing a stake of 3,738 shares — an estimated $209K sold.

Boothbay Fund Management first reported a position in TXG in Q4 2020 and held it in 3 quarters. The position peaked at $572K in Q4 2020. 274 funds tracked by Wall St. Rank hold TXG as of Q2 2023.

  • Boothbay Fund Management reported no remaining 10x Genomics position as of Q2 2023 after selling out during the quarter.
  • Boothbay Fund Management sold 3,738 10x Genomics shares in Q2 2023, an estimated $209K.
  • Boothbay Fund Management first reported a position in 10x Genomics in Q4 2020 and held it in 3 quarters.
  • Boothbay Fund Management's 10x Genomics position peaked at $572K in Q4 2020.
  • 274 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.